GSK, Scynexis partner to develop further Brexafemme for fungal infection
Brexafemme is a novel oral glucan synthase inhibitor that works with a distinct mechanism of action where it…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 Mar 23
Brexafemme is a novel oral glucan synthase inhibitor that works with a distinct mechanism of action where it…
31 Mar 23
Under the agreement, NovAliX will assume Galapagos’ research capabilities in Romainville, while the latter will retain the flexibility…
31 Mar 23
Through this work, the companies will support vital habitat for native wildlife, while also sustaining a robust beef…
31 Mar 23
The project will begin in Latin America with a call for applications across the region and the end-goal…
31 Mar 23
Almost two years ago, Carlsberg Denmark broke grounds on its new water recycling plant. Since then, by recycling…
30 Mar 23
HMC Capital, through its affiliate HealthCo Healthcare & Wellness REIT, will buy a portfolio of 11 private hospitals…
30 Mar 23
The prescription-to-OTC approval is backed by Human Factors study data, an updated Drug Facts label, pharmacovigilance data gathered…
29 Mar 23
The TYK2 inhibitor showed superior efficacy in improving skin clearance compared to placebo and twice-daily Otezla in the…
29 Mar 23
Bicycle Therapeutics will leverage its in-house phage platform to discover bicyclic peptide (Bicycle) to be developed into BRCs,…
29 Mar 23
The New Assay Will Screen Patients for Clinical Trials and Help Increase Data Analysis for Clinical Researchers